STREAM is a collaboration of researchers who share a common set of principles about the goals and methods for studying clinical translation. We apply empirical and philosophical tools for addressing scientific, ethical, and policy challenges in the development and translation of health technologies. Our members work in ethics, epidemiology, biology, psychology, and various medical specialties. The network is centered at McGill University, and has affiliates throughout North America and abroad.
Hutchinson N, Carlisle B, Doussau A, Bosan R, Gumnit E, MacPherson A, Fergusson DA, Kimmelman J. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration. JAMA network open. May 3, 2021.
Yu M, Montroy J, Fergusson D, Lalu M, Kimmelman J. Systematic and narrative review lead experts to different cancer trial predictions: a randomized trial. Journal of Clinical Epidemiology. December 17, 2020.
MacPherson A, Hutchinson N, Schneider O, Oliviero E, Feldhake E, Ouimet C, Sheng J, Awan F, Wang C, Papenburg J, Basta NE. Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases. Annals of Internal Medicine. November 24, 2020.
Kane PB, Benjamin DM, Barker RA, Lang AE, Sherer T, Kimmelman J. Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. Movement Disorders. October 1, 2020.
Kane PB, Moyer H, MacPherson A, Papenburg J, Ward B, Broomell S, Kimmelman J. Expert Forecasts of COVID-19 Vaccine Development Timelines. Journal of General Internal Medicine. September 28, 2020.
Why Canada's vaccine rollout won't be easy. Maclean's, December 8, 2020.
When it comes to COVID-19 vaccines, how good will be good enough? The National Post, October 28, 2020.
, , , , , , , ,
Benjamin D, Mandel DR, Barnes T, Krzyzanowska M, Leighl N, Tannock I, Kimmelman J. Can Oncologists Predict the Efficacy of Treatments in Randomized Trials?. The Oncologist. July 27, 2020.
Jonathan Kimmelman quoted by FiveThirtyEight about use of Ivermectin as a COVID-19 treatment.
Jonathan Kimmelman quoted by The Dallas Morning News about the testing of a new Covid-19 remedy backed by little evidence.
Jonathan Kimmelman quoted by Science about the use of Botox to ease depression.
Jonathan Kimmelman quoted by Fortune about the dangers of FDA emergency use authorizations.
Jonathan Kimmelman interviewed by The ASOS Press about important ethical considerations before launching a clinical cancer trials.
Jonathan Kimmelman quoted by Axios about the credibility of the AstraZeneca vaccine.
Jonathan Kimmelman quoted by The Harvard Crimson about reproducibility in science.
Jonathan Kimmelman quoted by CBC's Radio Canada about the impact of scientific papers published on pre-print servers.
Jonathan Kimmelman quoted in The National Post about Canada's decision to deviate from the dose schedules validated in clinical trials for COVID-19 vaccine administration.
Jonathan Kimmelman quoted in La Presse about the ethics of placebo-controlled clinical trials for approved COVID-19 vaccines.
Jonathan Kimmelman quoted in Discover magazine about COVID-19's impact on the scientific process.
Jonathan Kimmelman quoted in Open magazine about access to COVID-19 vaccines in low- and middle-income countries.
Jonathan Kimmelman quoted in The National Post about Pfizer's press release reporting 90% efficacy for their COVID-19 vaccine.
Jonathan Kimmelman quoted in The Sydney Morning Herald about the untested nature of Florida Man's COVID-19 treatment.